Venture capital (VC) funding into the U.K. life sciences sector reached £1.1 billion ($1.5 billion) in first quarter 2025, the strongest first quarter since 2021’s post-pandemic peak and a 36 percent increase versus fourth quarter 2024, according to Knight Frank.
Much of the recent capital investment was concentrated in just two VC deals, with Isomorphic Labs and Verdiva Bio attracting a combined £800 million ($1.1 billion) in funding. While this highlight renewed investor interest in the United Kingdom’s most innovative start-ups and scale-ups, it also underscores the need for more capital to flow across a broader range of companies. Spreading investment more widely will be critical to turbocharging growth, supporting a sustained rebound and ultimately driving a significant uplift in real estate take-up.
London, cementing its position as a European hub for science and innovation, accounted for a large share of the VC funding secured in the first qu
